Mainstay Grabs €30m For ReActiv8 German Launch, US PMA Trial
This article was originally published in Clinica
Mainstay Medical has topped up its coffers with an additional €30m ($34m) which it raised through a share placement with existing and new investors. The new capital, which will be added to the $10.4m available cash the company had as of May 31, will go towards launching in Germany its recently CE marked ReActiv8 implantable neurostimulation device for chronic low back pain.
Register for our free email digests: